Provided by Tiger Fintech (Singapore) Pte. Ltd.

Tscan Therapeutics, Inc.

1.59
+0.04002.58%
Post-market: 1.590.00000.00%18:40 EDT
Volume:606.00K
Turnover:987.48K
Market Cap:89.98M
PE:-0.71
High:1.72
Open:1.58
Low:1.53
Close:1.55
Loading ...

TScan Therapeutics Coverage Assumed by Morgan Stanley at Overweight

Dow Jones
·
15 Mar

TScan Therapeutics Inc : Morgan Stanley Assumes Coverage With Overweight Rating; Price Target $10

THOMSON REUTERS
·
14 Mar

TScan Therapeutics Is Maintained at Overweight by Barclays

Dow Jones
·
07 Mar

Barclays Remains a Buy on TScan Therapeutics (TCRX)

TIPRANKS
·
07 Mar

TScan Therapeutics Price Target Maintained With a $15.00/Share by HC Wainwright & Co.

Dow Jones
·
06 Mar

Promising Progress and Strategic Expansion Position TScan Therapeutics for Success

TIPRANKS
·
06 Mar

TScan Therapeutics Full Year 2024 Earnings: Misses Expectations

Simply Wall St.
·
06 Mar

BRIEF-TScan Therapeutics Inc Files For Mixed Shelf Of Up To $300 Million

Reuters
·
06 Mar

TScan Therapeutics Inc Files for Mixed Shelf of up to $300 Mln - SEC Filing

THOMSON REUTERS
·
06 Mar

TScan Therapeutics Is Maintained at Buy by Needham

Dow Jones
·
06 Mar

TScan Therapeutics Inc : Needham Cuts Target Price to $9 From $11

THOMSON REUTERS
·
05 Mar

TScan Therapeutics, Inc. (TCRX) Reports Q4 Loss, Lags Revenue Estimates

Zacks
·
05 Mar

TScan Therapeutics Q4 2024 GAAP EPS $(0.30) Misses $(0.27) Estimate, Sales $665.00K Miss $1.35M Estimate, Cash, Cash Equivalents, And Marketable Securities Of $290.1M To Fund Operations Into Q1 Of 2027

Benzinga
·
05 Mar

BRIEF-TScan Therapeutics Q4 Net Income USD -35.809 Million

Reuters
·
05 Mar

TScan Therapeutics Q4 Collaboration and License Revenue USD 665 Thousand

THOMSON REUTERS
·
05 Mar

TScan Therapeutics Inc: Cash, Cash Equivalents, and Marketable Securities Continue to Fund Operations Into Q1 2027

THOMSON REUTERS
·
05 Mar